CING
Cingulate Inc.- Healthcare
- Biotechnology
- $72M market cap
Forecast run · Nov 2, 2026Upside rank 659 of 3,170
Model Signal
ForecastQ Daily Probabilities
44.2%
71.7%
25.8%
Analyst Consensus
Recommendation2.17/5 Buy
Last price$4.98
Price target$9.00
Implied move+80.7%
Analysts6
ForecastQ Portfolios
CING is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.